CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 19 enrolled
Drug / intervention
Transcranial Magnetic Stimulation--DPFC first, MPFC second +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04449055
NCT04449055N/ACompleted

A Pilot Study of Transcranial Magnetic Stimulation for Treatment of Methamphetamine Use Disorders

Ryan M. Carnahan·interventional·Posted Jun 26, 2020·Updated Jan 16, 2026

In Brief

A clinical study evaluating Transcranial Magnetic Stimulation--DPFC first, MPFC second and Transcranial Magnetic Stimulation--MPFC first, DPFC second for Stimulant Dependence and 2 related conditions. Completed, enrolled 19 participants across 1 site.

Detailed Summary

This is a pilot study to test the feasibility of a recruitment strategy and study protocol to examine the effects of a dual target transcranial magnetic stimulation treatment in methamphetamine use disorder. The study will test intermittent theta burst stimulation (TBS) targeting the dorsolateral prefrontal cortex (DLPFC) combined with continuous TBS targeting the medial prefrontal cortex (MPFC) in people with methamphetamine use disorder (MAUD) who are engaged in psychosocial treatment. We will randomize the order in which these treatments are delivered at each treatment session, but all subjects will receive both treatments. Intermittent TBS targeting the DLPFC is approved by the Food and Drug Administration for major depressive disorder, and continuous TBS targeting the MPFC has been studied in cocaine use disorder. We will administer this dual target TBS daily for 2 weeks, followed by three times weekly for 2 weeks, and monitor depressive symptoms, anxiety, sleep, craving, quality of life, and methamphetamine use for three months. Changes in functional connectivity of brain circuits will be evaluated with functional magnetic resonance imaging (fMRI) before and after treatment. We expect to observe changes in connectivity between the DLPFC, MPFC, and other regions implicated in addiction and impulsivity. Furthermore, we will evaluate if baseline differences in functional connectivity can be used to predict response. Psychological tests focusing on state impulsivity and risk taking will be administered, and we expect to observe reductions in these characteristics after treatment. We will test this protocol in 20 patients recruited from clinical care settings at University of Iowa Hospitals and Clinics, University of New Mexico Health System, and University of Utah Health to illustrate the feasibility of recruitment and completing the protocol, to support an external funding proposal.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedJun 26, 2020
Enrollment StartOct 6, 2020
Primary CompletionMar 31, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 6.0 years ago

Interventions

Transcranial Magnetic Stimulation--DPFC first, MPFC seconddevice

Participants will undergo 16 treatments consisting of intermittent theta burst stimulation targeting the dorsolateral prefrontal cortex and continuous theta burst stimulation targeting the medial prefrontal cortex, over a 4-week period that coincides with psychosocial treatment for methamphetamine use disorder. Both treatments will be delivered at each TMS treatment visit. The DPFC first group will receive stimulation to the dorsolateral prefrontal cortex first and medial prefrontal cortex second at each treatment visit.

Transcranial Magnetic Stimulation--MPFC first, DPFC seconddevice

Participants will undergo 16 treatments consisting of intermittent theta burst stimulation targeting the dorsolateral prefrontal cortex and continuous theta burst stimulation targeting the medial prefrontal cortex, over a 4-week period that coincides with psychosocial treatment for methamphetamine use disorder. Both treatments will be delivered at each TMS treatment visit. The MPFC first group will receive stimulation to the medial prefrontal cortex first and DPFC second at each treatment visit.